211 related articles for article (PubMed ID: 21854754)
1. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome.
Josefsson A; Adamo H; Hammarsten P; Granfors T; Stattin P; Egevad L; Laurent AE; Wikström P; Bergh A
Am J Pathol; 2011 Oct; 179(4):1961-8. PubMed ID: 21854754
[TBL] [Abstract][Full Text] [Related]
2. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
Tidehag V; Hammarsten P; Egevad L; Granfors T; Stattin P; Leanderson T; Wikström P; Josefsson A; Hägglöf C; Bergh A
Eur J Cancer; 2014 Jul; 50(10):1829-1835. PubMed ID: 24726733
[TBL] [Abstract][Full Text] [Related]
3. High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting.
Hammarsten P; Dahl Scherdin T; Hägglöf C; Andersson P; Wikström P; Stattin P; Egevad L; Granfors T; Bergh A
PLoS One; 2016; 11(10):e0164016. PubMed ID: 27764093
[TBL] [Abstract][Full Text] [Related]
4. Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors.
Rizzardi AE; Vogel RI; Koopmeiners JS; Forster CL; Marston LO; Rosener NK; Akentieva N; Price MA; Metzger GJ; Warlick CA; Henriksen JC; Turley EA; McCarthy JB; Schmechel SC
Cancer; 2014 Jun; 120(12):1800-9. PubMed ID: 24668563
[TBL] [Abstract][Full Text] [Related]
5. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
6. High extent of O-GlcNAcylation in breast cancer cells correlates with the levels of HAS enzymes, accumulation of hyaluronan, and poor outcome.
Tiainen S; Oikari S; Tammi M; Rilla K; Hämäläinen K; Tammi R; Kosma VM; Auvinen P
Breast Cancer Res Treat; 2016 Nov; 160(2):237-247. PubMed ID: 27683279
[TBL] [Abstract][Full Text] [Related]
7. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer.
Lipponen P; Aaltomaa S; Tammi R; Tammi M; Agren U; Kosma VM
Eur J Cancer; 2001 May; 37(7):849-56. PubMed ID: 11313172
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells.
Simpson MA; Reiland J; Burger SR; Furcht LT; Spicer AP; Oegema TR; McCarthy JB
J Biol Chem; 2001 May; 276(21):17949-57. PubMed ID: 11278609
[TBL] [Abstract][Full Text] [Related]
9. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients.
Hammarsten P; Karalija A; Josefsson A; Rudolfsson SH; Wikström P; Egevad L; Granfors T; Stattin P; Bergh A
Clin Cancer Res; 2010 Feb; 16(4):1245-55. PubMed ID: 20145160
[TBL] [Abstract][Full Text] [Related]
10. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer.
Lokeshwar VB; Rubinowicz D; Schroeder GL; Forgacs E; Minna JD; Block NL; Nadji M; Lokeshwar BL
J Biol Chem; 2001 Apr; 276(15):11922-32. PubMed ID: 11278412
[TBL] [Abstract][Full Text] [Related]
11. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
12. Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy.
Wu JP; Huang WB; Zhou H; Xu LW; Zhao JH; Zhu JG; Su JH; Sun HB
Asian J Androl; 2014; 16(5):710-4. PubMed ID: 24875819
[TBL] [Abstract][Full Text] [Related]
13. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival.
Hägglöf C; Hammarsten P; Josefsson A; Stattin P; Paulsson J; Bergh A; Ostman A
PLoS One; 2010 May; 5(5):e10747. PubMed ID: 20505768
[TBL] [Abstract][Full Text] [Related]
14. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
[TBL] [Abstract][Full Text] [Related]
15. Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis.
Bharadwaj AG; Rector K; Simpson MA
J Biol Chem; 2007 Jul; 282(28):20561-72. PubMed ID: 17502371
[TBL] [Abstract][Full Text] [Related]
16. High stroma-derived WNT5A is an indicator for low-risk prostate cancer.
Kisel W; Conrad S; Borkowetz A; Furesi G; Füssel S; Sommer U; Rauner M; Thomas C; Baretton GB; Schaser KD; Hofbauer C; Hofbauer LC
FEBS Open Bio; 2021 Apr; 11(4):1186-1194. PubMed ID: 33639039
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.
Ekici S; Cerwinka WH; Duncan R; Gomez P; Civantos F; Soloway MS; Lokeshwar VB
Int J Cancer; 2004 Oct; 112(1):121-9. PubMed ID: 15305383
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival.
Auvinen P; Rilla K; Tumelius R; Tammi M; Sironen R; Soini Y; Kosma VM; Mannermaa A; Viikari J; Tammi R
Breast Cancer Res Treat; 2014 Jan; 143(2):277-86. PubMed ID: 24337597
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer.
Posey JT; Soloway MS; Ekici S; Sofer M; Civantos F; Duncan RC; Lokeshwar VB
Cancer Res; 2003 May; 63(10):2638-44. PubMed ID: 12750291
[TBL] [Abstract][Full Text] [Related]
20. High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting.
Nilsson M; Hägglöf C; Hammarsten P; Thysell E; Stattin P; Egevad L; Granfors T; Jernberg E; Wikstrom P; Halin Bergström S; Bergh A
PLoS One; 2015; 10(10):e0140985. PubMed ID: 26501565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
